Filing Date: August 11, 2000

Title: CEA/NCA-BASED DIFFERENTIATION CANCER THERAPY

Remarks

As requested by the Examiner, claims 12, 14-15, 20-21, and 24-25 have been amended so that they properly contain sequence identification numbers therein. Claims 12-25 are currently pending.

This Supplemental Preliminary Amendment and the above-referenced substitute SEQUENCE LISTING are filed in part to conform the above-referenced application to the requirements of 37 C.F.R. §§ 1.821 - 1.825. In accordance with 37 C.F.R. § 1.821(e), a copy of the above-submitted substitute SEQUENCE LISTING in ASCII computer readable form is also submitted on even date herewith to the U.S. Patent and Trademark Office, Mail Stop Sequence Listing, P.O. Box 1450, Alexandria, VA 22313-1450. Applicant believes that the contents of the paper version of the SEQUENCE LISTING submitted herewith, and the computer readable form being submitted to Mail Stop Sequence, are the same and do not include new matter.

Additionally, the substitute sequence listing submitted herewith was amended to correct typographical errors (e.g., SEQ ID NOs:17 and 18 had a C instead of a G following "GYSWYK"). The sequences now presented are based on the sequences as originally filed, except for the typographical error noted for SEQ ID NO:5 in the remarks of the Supplemental Preliminary Amendment of October 31, 2002.

Applicant also notes that SEQ ID NOs:25 to 30 have been added and the sequences are fully supported by the application as originally filed. For example, SEQ ID NOs:25 to 29 relate to the third subdomain of CEA/NCA (see, for example, Figure 9) and SEQ ID NO:30 is the recombinant N-terminus sequence of CEA having the third subdomain thereof mutated from QND to QNN (see, Fig. 10F). Thus, SEQ ID NO:30 is identical to SEQ ID NO:5 except for the substitution of QNN for the wild-type QND.

Applicant reiterates that no new matter has been entered by the instant amendment.

Serial Number: 09/637530 Filing Date: August 11, 2000

Title: CEA/NCA-BASED DIFFERENTIATION CANCER THERAPY

Conclusion

If any questions remain with respect to the present application, the Examiner is requested to contact Applicant's Representatives at the below-listed number.

Respectfully Submitted,

CLIFFORD P. STANNERS ET AL.

By their Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A. P.O. Box 2938
Minneapolis, MN 55402
(612) 373-6905

Date Aug. 11, 2003

By Morrique M. Perdok

Reg. No. 42,989

CERTIFICATE UNDER 37 CFR § 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelop addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this August 2003

Name Korrycta H. H. Hman

Signature Janoa